The results showed that the cancers from 17 patients (26.98%) were TRPC3 positive only in mesenchyme cells (MCs), those from 3 patients (4.76%) were positive only in tumor cells (TCs), and the cancers from 26 patients (41.27%) were positive for TRPC3 expression in both mesenchymal and tumor cells (double positive, DP). This evidence concerns the gene TRPC3 and cancer.